Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ONO-6818 Cortech/Ono.

Alexandre Trifilieff¹

¹Novartis Respiratory Research Centre, Horsham, West Sussex, UK. alexandre.trifilieff@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)

|September 5, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Journal of medicinal chemistry·2015

Same author

Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.

Toxicology and applied pharmacology·2015

Same author

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

Bioorganic & medicinal chemistry letters·2014

Same author

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.

Bioorganic & medicinal chemistry letters·2012

Same author

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.

Journal of medicinal chemistry·2012

Same author

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

The Journal of pharmacology and experimental therapeutics·2012

ONO-6818, an orally bioavailable neutrophil elastase inhibitor, is being investigated for inflammatory conditions like rheumatoid arthritis and COPD. Early-stage clinical trials were ongoing in Japan and the US, with unconfirmed reports suggesting progression to Phase II studies.

Area of Science:

Pharmacology
Drug Development
Inflammation Research

Background:

ONO-6818 is a neutrophil elastase inhibitor developed for inflammatory diseases.
It is orally bioavailable and licensed from Cortech by Ono Pharmaceuticals.
Potential therapeutic applications include rheumatoid arthritis, inflammatory bowel disease, and COPD.

Purpose of the Study:

To evaluate the safety and efficacy of ONO-6818 in early-phase clinical trials.
To assess the compound's potential for treating inflammatory conditions.

Main Methods:

Phase I clinical trials conducted in Japan and the US.
Ongoing investigations into ONO-6818's pharmacokinetic and pharmacodynamic properties.

Main Results:

Related Experiment Videos

Phase I trials for COPD were initiated in Japan by December 1999.
Phase I trials were ongoing in Japan and the US as of September 2001.
Unconfirmed reports in June 2002 indicated progression to Phase II trials in Japan and preparation for Phase II in the US.

Conclusions:

ONO-6818 demonstrated progression through early-stage clinical development for COPD.
Further investigation in Phase II trials was anticipated for the US and Japan.